Idera Pharmaceuticals Inc. (IDRA)

2.59
NASDAQ : Health Technology
Prev Close 2.61
Day Low/High 2.53 / 2.64
52 Wk Low/High 2.25 / 10.95
Avg Volume 359.80K
Exchange NASDAQ
Shares Outstanding 28.02M
Market Cap 73.14M
EPS -2.20
P/E Ratio N/A
Div & Yield N.A. (N.A)
4 Stocks Under $10 to Trade for Breakouts

4 Stocks Under $10 to Trade for Breakouts

These under-$10 stocks look ready to break out and trade higher from current levels.

Idera Pharmaceuticals Reports Second Quarter 2014 Financial Results And Provides Corporate Update

Idera Pharmaceuticals Reports Second Quarter 2014 Financial Results And Provides Corporate Update

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing nucleic acid therapeutics for rare diseases, today reported financial and operational results for the quarter ended June...

Idera Pharmaceuticals And The Myositis Association Join Forces To Advance The Clinical Development Of A Novel TLR Antagonist, IMO-8400, For The Treatment Of Myositis

Idera Pharmaceuticals And The Myositis Association Join Forces To Advance The Clinical Development Of A Novel TLR Antagonist, IMO-8400, For The Treatment Of Myositis

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and rare diseases, and The Myositis Association (TMA), the only...

4 Under-$10 Stocks to Trade for Breakouts

4 Under-$10 Stocks to Trade for Breakouts

These stocks under $10 are within range of triggering breakout trades.

Idera Pharmaceuticals And Collaborators Publish Promising Preclinical Data Targeting MicroRNA With Gene Silencing Oligonucleotide Technology

Idera Pharmaceuticals And Collaborators Publish Promising Preclinical Data Targeting MicroRNA With Gene Silencing Oligonucleotide Technology

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and rare diseases, today announced the publication of promising...

Idera Pharmaceuticals To Host Conference Call And Webcast To Report Second Quarter 2014 Financial Results

Idera Pharmaceuticals To Host Conference Call And Webcast To Report Second Quarter 2014 Financial Results

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and orphan diseases, today announced that the Company will host a...

Interesting IDRA Put And Call Options For September 20th

Interesting IDRA Put And Call Options For September 20th

Investors in Idera Pharmaceuticals Inc saw new options begin trading this week, for the September 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IDRA options chain for the new September 20th contracts and identified one put and one call contract of particular interest.

Idera Pharmaceuticals To Be Added To The Russell 3000® And Russell 2000® Indexes

Idera Pharmaceuticals To Be Added To The Russell 3000® And Russell 2000® Indexes

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biopharmaceutical company developing nucleotide therapeutics for patients with cancer and orphan diseases, today announced that it will be added to the...

First Week Of February 2015 Options Trading For Idera Pharmaceuticals (IDRA)

First Week Of February 2015 Options Trading For Idera Pharmaceuticals (IDRA)

Investors in Idera Pharmaceuticals Inc saw new options become available this week, for the February 2015 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

5 Stocks Setting Up to Break Out

5 Stocks Setting Up to Break Out

These stocks look poised to break out and trade higher from current level.s

Idera Pharmaceuticals To Participate In A Panel Discussion At The Piper Jaffray GenomeRx Symposium

Idera Pharmaceuticals To Participate In A Panel Discussion At The Piper Jaffray GenomeRx Symposium

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing nucleotide therapeutics for patients with cancer and orphan diseases, today announced that Sudhir Agrawal, D.

Idera Pharmaceuticals To Present At The Nucleic Acid Summit 2014

Idera Pharmaceuticals To Present At The Nucleic Acid Summit 2014

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing novel nucleic acid therapeutics for orphan diseases, today announced that Walter Strapps, Ph.

Idera Pharmaceuticals To Present At The Jefferies 2014 Global Healthcare Conference

Idera Pharmaceuticals To Present At The Jefferies 2014 Global Healthcare Conference

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing novel nucleic acid therapeutics for orphan diseases, today announced that Company management will present at the...

First Week of July 19th Options Trading For Idera Pharmaceuticals (IDRA)

First Week of July 19th Options Trading For Idera Pharmaceuticals (IDRA)

Investors in Idera Pharmaceuticals Inc saw new options begin trading this week, for the July 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IDRA options chain for the new July 19th contracts and identified one put and one call contract of particular interest.

Idera Pharmaceuticals Reports First Quarter 2014 Financial Results And Provides Update On Key Programs And Business Strategy

Idera Pharmaceuticals Reports First Quarter 2014 Financial Results And Provides Update On Key Programs And Business Strategy

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing novel nucleic acid therapeutics for orphan diseases, today reported its financial and operational results for the...

Insider buying on the rise at these 5 stocks with earnings next week

Insider buying on the rise at these 5 stocks with earnings next week

James Dennin, Kapitall: Stocks are rebounding today on strong earnings. We looked for insider buying spikes among stocks with earnings [...]

Idera Announces Agreement With Abbott To Develop A Companion Diagnostic For IMO-8400 In Genetically Defined Forms Of B-cell Lymphoma

Idera Announces Agreement With Abbott To Develop A Companion Diagnostic For IMO-8400 In Genetically Defined Forms Of B-cell Lymphoma

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biotechnology company developing novel therapeutics for orphan patient populations with B-cell lymphomas and autoimmune diseases, announced today that it has...

Idera Pharmaceuticals To Host Conference Call And Webcast To Report First Quarter 2014 Financial Results And Provide A Detailed Pipeline Review

Idera Pharmaceuticals To Host Conference Call And Webcast To Report First Quarter 2014 Financial Results And Provide A Detailed Pipeline Review

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical stage biopharmaceutical company developing novel therapeutics for orphan patient populations with B-cell lymphomas and autoimmune diseases, today announced that the...

Idera Expands Management Team With Three Key Hires

Idera Expands Management Team With Three Key Hires

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical stage biopharmaceutical company developing novel therapeutics for orphan patient populations with B-cell lymphomas and autoimmune diseases, today announced the...

Will Idera Pharmaceuticals (IDRA) Stock Sustain Today's Rally?

Will Idera Pharmaceuticals (IDRA) Stock Sustain Today's Rally?

Idera Pharmaceuticals (IDRA) surged Tuesday on a positive day for healthcare stocks after the company had remained relatively flat since last week.

Interesting IDRA Put And Call Options For June 21st

Interesting IDRA Put And Call Options For June 21st

Investors in Idera Pharmaceuticals Inc saw new options become available this week, for the June 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IDRA options chain for the new June 21st contracts and identified one put and one call contract of particular interest.

Today's Dead Cat Bounce Stock Is Idera Pharmaceuticals (IDRA)

Today's Dead Cat Bounce Stock Is Idera Pharmaceuticals (IDRA)

Trade-Ideas LLC identified Idera Pharmaceuticals (IDRA) as a "dead cat bounce" (down big yesterday but up big today) candidate

Idera Presents Preclinical Data At AACR Showing IMO-8400 Inhibits Tumor Growth And Survival Signaling In B-cell Lymphoma Cells With Oncogenic MYD88 L265P Mutation

Idera Presents Preclinical Data At AACR Showing IMO-8400 Inhibits Tumor Growth And Survival Signaling In B-cell Lymphoma Cells With Oncogenic MYD88 L265P Mutation

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today presented new preclinical data demonstrating the ability of its Toll-like receptor (TLR) antagonist, IMO-8400, to inhibit the survival and proliferation of B-cell...

Idera Pharmaceuticals (IDRA) Marked As A Dead Cat Bounce Stock

Idera Pharmaceuticals (IDRA) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified Idera Pharmaceuticals (IDRA) as a "dead cat bounce" (down big yesterday but up big today) candidate

TheStreet Quant Rating: D (Sell)